RNA-Sequencing Reveals a Distinct Transcriptomic Signature for Giant Cell Myocarditis and Identifies Novel Druggable Targets

Circ Res. 2021 Jul 23;129(3):451-453. doi: 10.1161/CIRCRESAHA.121.319317. Epub 2021 Jun 14.

Authors

Affiliations

¹ Division of Cardiovascular Medicine (K.A., J.Q., K.H.S., J.L., J.M.), Vanderbilt University Medical Center, Nashville, TN.
² Department of Pathology, Microbiology, and Immunology, and Department of Biostatistics (Y.W., Y.X.), Vanderbilt University Medical Center, Nashville, TN.
³ Department of Medicine (M.L.A., J.M.B.), Vanderbilt University Medical Center, Nashville, TN.

^# Contributed equally.

No abstract available

Keywords: giant cells; myocarditis; transcriptome.

Publication types

Letter
Research Support, N.I.H., Extramural

MeSH terms

Abatacept / therapeutic use
Adult
Apoptosis
Clinical Trials as Topic
Drug Development*
Female
Giant Cells / metabolism
Humans
Interleukin 1 Receptor Antagonist Protein / therapeutic use
Male
Middle Aged
Myocarditis / drug therapy
Myocarditis / genetics
Myocarditis / metabolism*
Myocardium / metabolism
Myocardium / pathology
Network Pharmacology
Oxidative Phosphorylation
Transcriptome*

Substances

Interleukin 1 Receptor Antagonist Protein
Abatacept

Grants and funding